悦康藥業(688658.SH):注射用蘭索拉唑通過仿製藥一致性評價
格隆匯3月23日丨悦康藥業(688658.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的關於注射用蘭索拉唑的《藥品補充申請批准通知書》(通知書編號:2022B01270),該藥品通過仿製藥質量和療效一致性評價。
注射用蘭索拉唑適用於口服療法不適用的伴有出血的胃、十二指腸潰瘍、急性應激潰瘍、急性胃粘膜損傷。
注射用蘭索拉唑通過仿製藥一致性評價,是公司研發、生產及質量管理體系等綜合實力的體現,有利於擴大公司產品的市場份額,提升市場競爭力。同時為公司後續一致性評價產品研究積累了豐富的經驗,進一步提升了公司整體研發水平和研發能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.